WallStSmart

Arrowhead Pharmaceuticals Inc (ARWR)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Arrowhead Pharmaceuticals Inc generates 83729% more annual revenue ($622.01M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -48.4%. RVMD earns a higher WallStSmart Score of 24/100 (F).

ARWR

Avoid

23

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 5.0Quality: 5.0
Piotroski: 5/9Altman Z: 0.29

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ARWR0 strengths · Avg: 0/10

No standout strengths identified

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

ARWR4 concerns · Avg: 2.5/10
Price/BookValuation
16.7x4/10

Trading at 16.7x book value

Return on EquityProfitability
-49.0%2/10

ROE of -49.0% — below average capital efficiency

Revenue GrowthGrowth
-86.4%2/10

Revenue declined 86.4%

Altman Z-ScoreHealth
0.292/10

Distress zone — elevated risk

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ARWR

ARWR has a balanced fundamental profile.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : ARWR

The primary concerns for ARWR are Price/Book, Return on Equity, Revenue Growth. Debt-to-equity of 2.24 is elevated, increasing financial risk.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

ARWR profiles as a turnaround stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

ARWR is growing revenue faster at -86.4% — sustainability is the question.

ARWR generates stronger free cash flow (82M), providing more financial flexibility.

Bottom Line

RVMD scores higher overall (24/100 vs 23/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Arrowhead Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Arrowhead Pharmaceuticals, Inc. develops drugs for the treatment of intractable diseases in the United States. The company is headquartered in Pasadena, California.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?